We take a look back at the year in sarcoma news and research and bring you the top stories of 2016, as well as highlight a case study on a rare subtype and a review article from the journal ONCOLOGY.
Sarcoma Year In Review 2016
In this slide show we highlight some of the top news on sarcoma in 2016, including the first frontline FDA approval in 40 years, and studies on imaging in Ewing sarcoma, maintenance chemotherapy in osteosarcoma, and more.
A case study found that a patient with an inflammatory myofibroblastic tumor and a chromoplectic TPM3-ALK rearrangement that may be involved in tumorigenesis had a strong response to the ALK inhibitor ceritinib.
A trial of five rare sarcoma subtypes found that though dasatinib failed to achieve progression-free survival goals, more than half of patients with certain subtypes did have reasonably good survival outcomes.
The addition of palifosfamide to doxorubicin failed to improve survival in a phase III trial of patients with metastatic soft-tissue sarcoma.
Alisertib yielded promising progression-free survival in advanced/metastatic soft-tissue sarcoma patients, though it did not meet its primary response rate endpoint.
A 37-year-old Lebanese male with no significant past medical history initially presented with an increase in abdominal girth over a few weeks with worsening shortness of breath, nausea, and intermittent vomiting.
Zoledronate in combination with chemotherapy failed to improve outcomes over chemotherapy alone in patients with osteosarcoma.
Improvements in neoadjuvant therapy for soft-tissue sarcomas will require the development of more efficacious systemic therapies and, if possible, the performance of histology-specific, prospective, randomized clinical trials to advance the field.
The aim of this review is to discuss current neoadjuvant treatment options for soft-tissue sarcomas.